Cell therapy using bone marrow derived cell for liver cirrhosis patient
Shuji Terai1,2, Taro Takami2, Atsunori Tsuchiya1, Isao Sakaida2.
1Division of Gastroenterology and Hepatolog, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan; 2Department of Gastroenterology & Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
We have developed autologous bone marrow cell infusion (ABMi) therap for liver citrrhosis patients using non-cultured autologous whole bone marrow (BM) cells, and reported the efficacy and safety of this approach. However, ABMi therapy involves BM aspiration under general anesthesia, and is not indicated for patients for whom general anesthesia is difficult. We therefore aimed to develop a less-invasive liver regeneration therapy in which cells having curative effects on liver cirrhosis are isolated and cultured from a small amount of autologous BM aspirated under local anesthesia and infused back into the same patient, that the indications would be able to be expanded. We revealed that the infusion of cultured human BM-derived CD73/CD90/CD105 positive and CD45 negative cells with fetal bovine serum-containing D-MEM medium, which were having mesenchymal characteristics, reduced hepatic fibrosis in the immunodeficientcirrhotic mice. Oxidative stress in co-cultured human stellate cells was reduced with human mesenchymal stem cells in vitro. For the clinical trial using cultured BM-derived mesenchymal stem cells, we are preparing safety evaluation guidelines and a system conforming to Standard Operating Procedure at a Good Manufacturing Practice-grade cell-processing center in our university hospital. We get the approval of this clinical study and started this study. Here, we present the current status and prospects for our liver regeneration therapy using autologous BM-derived cells.
15:30 - 17:00
|Stem Cells Bioengineering, and Preclinical Work||Cell therapy using bone marrow derived cell for liver cirrhosis patient||Room 111-112|